Key facts
- YNIOS Pharma’s last known valuation is $6.4M (Dec 2024).
- It has raised $840K; the latest was Angel (individual) ($730K) in Dec 2024.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for YNIOS Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for YNIOS Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About YNIOS Pharma
Operator of a biotechnology platform intended to provide treatments for acute and chronic diseases. The company's platform utilizes a proprietary ionic compound to develop new oral and parenteral treatments for diseases where neuronal degeneration is caused by inflammation and supports the preclinical development of multiple pathologies linked to both acute and chronic inflammation, enabling patients to get treatments with more effective and better-tolerated therapeutic alternatives.
- Sector
- Healthcare
- HQ
- Verlaine, Belgium
- Founded
- 2022
- Website
- yniospharma.com/
- Ownership
- Privately Held (backing)
YNIOS Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in YNIOS Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on YNIOS Pharma in its N-PORT filings yet. We sweep new filings monthly.